PMID: 9438639Jan 23, 1998Paper

Bladder augmentation can be problematic with renal failure and transplantation

Pediatric Nephrology : Journal of the International Pediatric Nephrology Association
E J AlfreyS B Conley

Abstract

Ten consecutive patients with failure of urinary bladder augmentation (UBA) performed either prior to or after reaching end-stage renal disease (ESRD) were studied. Seven patients developed increased hydroureteronephrosis, infectious complications, and advanced to ESRD after UBA. The mean time to development of ESRD in patients who had UBA performed with moderate chronic renal failure (CRF) was 1.8 years. The UBAs in all seven patients were taken down prior to transplantation. Subsequently, five of these UBA-takedown patients have received kidney grafts and all have stable, good renal function. Three patients had their UBA performed after they reached ESRD, in preparation for renal transplantation. All three of these patients experienced recurrent urosepsis following transplantation, resulting in death in one patient and loss of graft in another. The third patient will undergo takedown of the UBA. This study suggests that UBA may possibly not be the best option for patients with moderate CRF and those awaiting transplantation.

Citations

Nov 18, 2005·Der Urologe. Ausg. A·T F FullerM Giessing
Jan 28, 2009·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Sun-Young AhnVivian Reznik
Jun 18, 1999·Transplantation Proceedings·O Salvatierra
Sep 23, 2003·The Journal of Urology·William DeFoorCurtis Sheldon
May 15, 2007·The Journal of Urology·Abbas BasiriFarhat Farrokhi
Jan 26, 2005·BJU International·Christopher R J Woodhouse
Dec 17, 2008·BJU International·Nenad DjakovicMarkus Hohenfellner
Feb 3, 2005·Transplantation Proceedings·R E PowerD M Little
May 20, 2015·The Journal of Urology·Ahmed AbdelhalimAshraf T Hafez
Aug 11, 2015·Pediatric Transplantation·María Consuelo SierraltaFrancisco Ossandón
Jul 5, 2006·Seminars in Pediatric Surgery·Oscar SalvatierraWaldo Concepcion
Mar 22, 2006·Transplantation Proceedings·F T AkiS Tekgul
May 20, 1999·The Journal of Urology·D B LashleyJ A Mowry
Feb 26, 1999·The Journal of Urology·H P KooD A Bloom
Aug 15, 2014·International Journal of Urology : Official Journal of the Japanese Urological Association·Masaki MuramatsuAtsushi Aikawa
Feb 24, 2015·Journal of Pediatric Urology·L E Jesus, J L Pippi Salle
Jan 7, 2015·The Journal of Urology·Katherine C HubertMark P Cain
Aug 25, 1999·Current Opinion in Urology·M HohenfellnerJ W Thüroff
Apr 4, 2017·International Journal of Nephrology·Shahbaz MehmoodWaleed Mohammad Altaweel
Jul 25, 2000·BJU International·R E PowerD P Hickey
Jul 9, 2002·Pediatric Transplantation·Eric A KurzrockUNKNOWN Lavjay Butani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.